- Home
- IDAI vs KZIA Comparison
IDAI vs KZIA Comparison
Compare IDAI & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDAI
- KZIA
- Stock Information
- Founded
- IDAI 2016
- KZIA 1994
- Country
- IDAI United States
- KZIA Australia
- Employees
- IDAI N/A
- KZIA N/A
- Industry
- IDAI Computer Software: Prepackaged Software
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- IDAI Technology
- KZIA Health Care
- Exchange
- IDAI Nasdaq
- KZIA Nasdaq
- Market Cap
- IDAI 7.7M
- KZIA 9.0M
- IPO Year
- IDAI N/A
- KZIA 1999
- Fundamental
- Price
- IDAI $2.86
- KZIA $8.07
- Analyst Decision
- IDAI
- KZIA Strong Buy
- Analyst Count
- IDAI 0
- KZIA 2
- Target Price
- IDAI N/A
- KZIA $14.00
- AVG Volume (30 Days)
- IDAI 25.9K
- KZIA 17.4K
- Earning Date
- IDAI 08-14-2025
- KZIA 06-05-2025
- Dividend Yield
- IDAI N/A
- KZIA N/A
- EPS Growth
- IDAI N/A
- KZIA N/A
- EPS
- IDAI N/A
- KZIA N/A
- Revenue
- IDAI $3,366,415.00
- KZIA $1,549,158.00
- Revenue This Year
- IDAI $25.13
- KZIA N/A
- Revenue Next Year
- IDAI $48.09
- KZIA $49.25
- P/E Ratio
- IDAI N/A
- KZIA N/A
- Revenue Growth
- IDAI N/A
- KZIA 248983.08
- 52 Week Low
- IDAI $1.43
- KZIA $2.86
- 52 Week High
- IDAI $18.75
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- IDAI 50.28
- KZIA 50.42
- Support Level
- IDAI $2.85
- KZIA $7.15
- Resistance Level
- IDAI $3.06
- KZIA $8.90
- Average True Range (ATR)
- IDAI 0.17
- KZIA 0.64
- MACD
- IDAI 0.00
- KZIA 0.02
- Stochastic Oscillator
- IDAI 50.63
- KZIA 69.03
About IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.